Custodiol-N
Drugheart will preserved in and will be treated with Custodiol-N solution
Other names: Solution for organ preservation in transplantation
NCT Number: NCT06032195
The goal of this prospective randomized single blind multicenter phase II study is to compare organ perfusion with Custodiol-N and Custodiol in heart transplantation in children of all ages (birth to <18 years) being listed on the waiting list for heart transplantation. The main question it aims to answer is:
to compare the safety of Custodiol-N in heart transplantation in children in comparison to its precursor product Custodiol.
Participants will receive either a heart to be transplanted, either perfused with Custodiol-N or Custodiol to Researchers will compare the two solutions to see if the new solution Custodiol-N is safe in heart transplantation in children.
Interested in participating?
Request Info24 hour–17 year
All sexes
Interventional
Phase 2
Deutsches Herzzentrum der Charité, Berlin, Germany
Orthotopic Heart transplantation (or cardiac transplantation) is a procedure performed in patients with end stage heart failure when other treatments have failed.
The surgical procedures for orthotopic heart transplantation are essentially the same in adult and paediatric patients . Due to anatomical variants in congenital heart disease the procurement procedure may be modified with regard to the extent of the Vena cava superior and the great vessels. In implantation most frequently the bicaval technique is used but the biatrial technique which is leaving the back wall of both atria in situ may also be employed.
A main difference between adult and paediatric heart transplantation (HTx) are the indications for transplantation: In adults the majority of patients undergo HTx as treatment of end stage heart failure due to cardiomyopathy or severe coronary artery disease when other treatments have failed. Infants younger than one year of age congenital heart disease (CHD) is the most common diagnosis representing more than every second case followed by dilated cardiomyopathy (DCM) in more than one third of cases. In older patients DCM is the most frequent underlying diagnosis. CHD may include patients who have undergone corrective surgery and in whom myocardial dysfunction develops later .
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
heart will preserved in and will be treated with Custodiol-N solution
Other names: Solution for organ preservation in transplantation
heart will preserved in and will be treated with Custodiol solution
Other names: Solution for organ preservation in transplantation
Time frame: up to 3 months
Safety assessment
Time frame: up to day 7 after release of the aortic cross clamp
vital parameters
Time frame: up to day 7 after release of the aortic cross clamp
vital parameters
Time frame: up to day 7 after release of the aortic cross clamp
vital parameters
Time frame: up to day 7 after release of the aortic cross clamp
laboratory tests
Time frame: up to day 7 after release of the aortic cross clamp
laboratory tests
Time frame: from termination of cardiopulmonary bypass until transfer to intensive care unit
Haemodynamics
Time frame: from termination of cardiopulmonary bypass until transfer to intensive care unit
Haemodynamics
Time frame: from termination of cardiopulmonary bypass until transfer to intensive care unit
Haemodynamics
Time frame: from termination of cardiopulmonary bypass until transfer to intensive care unit
Haemodynamics
Time frame: up to 12 months
survival
Time frame: up to 12 months
Graft survival
Time frame: up to 12 months
return to intensive care unit
Time frame: up to 12 months
duration of stay in intensive care unit
Time frame: up to day 7
(yes/no)
Time frame: up to 12 months
(yes/no)
Time frame: up to day 7
(yes/no)
Time frame: up to day 7
(yes/no)
Time frame: up to 12 months
Device therapy (each yes/no)
Time frame: up to 12 months
Device therapy (each yes/no)
Time frame: up to 12 months
Device therapy (each yes/no)
Time frame: up to day 7
Echocardiographic markers of function and rejection
Time frame: up to day 7
Echocardiographic markers of function and rejection
Time frame: up to day 7
occurrence, severity, type
Contact information is provided by the study sponsor or research team.
Dr. F. Köhler Chemie GmbH
Industry
A Prospective Randomized Single Blind Multicenter Phase II Study of Organ Perfusion With Custodiol-N Compared With Custodiol in Heart Transplantation in Children
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06774365
HLA Antigens, Heart Transplantation
Bari, Italy
View Trial DetailsNCT05909150
Acute Kidney Injury, Female Urogenital Diseases
São Paulo, Brazil
View Trial DetailsNCT07531784
Heart Transplant Rejection, Heart Transplantation
Stockholm, Sweden
View Trial DetailsNCT05729009
Heart Transplantation
Rio de Janeiro, Brazil
View Trial Details